期刊文献+

盐酸莫西沙星片在健康志愿者体内两种条件下的药动学研究 被引量:7

Pharmacokinetics of Moxifloxacin hydrochloride tablets in the healthy volunteers under two conditions
原文传递
导出
摘要 目的研究盐酸莫西沙星片在健康志愿者体内两种条件下的药动学。方法采用随机交叉自身对照试验设计,24名健康男性志愿者随机交叉单剂量空腹(或餐后)口服400 mg盐酸莫西沙星片。采用HPLC-UV法测定受试者血浆中莫西沙星的浓度,计算药动学参数,评价制剂在两种条件下的药动学行为。结果空腹条件下,盐酸莫西沙星片的主要药动学参数为:Tmax=1.55±0.96 h,Cmax=3.45±0.88μg·m L-1,AUC0-t=58.77±13.02μg·m L-1·h,AUC0-∞=60.50±13.71μg·m L-1·h;餐后条件下,盐酸莫西沙星片的主要药动学参数为:Tmax=2.66±1.48 h,Cmax=3.16±0.70μg·m L-1,AUC0-t=57.01±9.95μg·m L-1·h,AUC0-∞=59.00±10.60μg·m L-1·h。结论餐后与空腹条件相比,除了Tmax有所延迟外,其余药动学参数均无太大差别,表明食物可能会减缓盐酸莫西沙星的吸收。 OBJECTIVE To investigate the pharmacokinetics of Moxifloxacin hydrochloride tablet( MH) in healthy volunteers under two conditions. METHODS A single oral dose of 400 mg of MH was given respectively to 24 healthy male volunteers according to an open randomized crossover design under fasting or postprandial condition. The plasma concentration of MH was determined by HPLC-UV method,and the pharmacokinetic parameters were calculated. The pharmacokinetic behaviors under two conditions were estimated.RESULTS The main pharmacokinetic parameters of MH under fasting condition were as followings: Tmaxwas 1. 55 ± 0. 96 h,Cmaxwas3. 45 ± 0. 88 μg·mL^-1,AUC0- twas 58. 77 ± 13. 02 μg·mL^-1·h,AUC0- ∞was 60. 50 ± 13. 71 μg·mL^-1·h. The main pharmacokinetic parameters of MH under postprandial condition were as followings: Tmaxwas 2. 66 ± 1. 48 h,Cmaxwas 3. 16 ± 0. 70 μg·mL^-1,AUC0- t was 57. 01 ± 9. 95 μg·mL^-1·h,AUC0- ∞was 59. 00 ± 10. 60 μg·mL^-1·h. CONCLUSION Compared to the fasting condition,except that the Tmaxof postprandial condition was delayed,other pharmacokinetic parameters barely have difference between each other. The results show that food may delayed the absorption of MH.
出处 《华西药学杂志》 CAS CSCD 2016年第1期72-74,共3页 West China Journal of Pharmaceutical Sciences
关键词 莫西沙星 药动学 药动学参数 高效液相色谱法 Moxifloxacin Pharmacokinetic Pharmacokinetic parameters HPLC
  • 相关文献

参考文献5

  • 1Tatar US. High - performance liquid chromatography assay for moxifloxacin : Pharmacokinetics in human plasma [ J ]. J Pharmac Biomed analysis ,2007,43 ( 1 ) :320 - 324.
  • 2姚苑梅,徐玉红,李东,钟芬,杨蕾萍,王启平,王大果,阳宇,郑学庆.盐酸莫西沙星片在健康人体的药动学研究[J].中国药师,2010,13(6):793-796. 被引量:12
  • 3Hemanth KAK, Ramachandran G. Simple and rapid liquid chro- matography method for determination of moxifloxacin in plasma [ J]. J Chromatography B ,2009,877 ( 11 ) : 1205 - 1208.
  • 4Sultana N, Arayne M S, Akhtar M, et al. High - performance liquid chromatography assay for Moxifloxaein in bulk, pharmaceu- tical formulations and serum : Application to in vitro metal interac- tionsl J]. J Chin Chem Soc,2010,57(4A) :708 -717.
  • 5张卫,苏东晖,钟华玉,蒋银送.盐酸莫西沙星片剂的血药浓度及药动学分析[J].福建医药杂志,2013,35(3):68-71. 被引量:2

二级参考文献16

  • 1张吟,陈一农,陈文发.固相萃取-高效液相色谱法测定人血清中莫西沙星浓度[J].中国医院药学杂志,2007,27(4):481-483. 被引量:24
  • 2Julia A,Balfour B,Wiseman LR.Moxifloxacin[J].Drugs,1999,57(3):363-373.
  • 3Gillian MK,Lesley JS.Moxifloxacin:a review of its use in the management of bacterial infections[J].Drugs,2004,64 (20):2347-2377.
  • 4Krasemann C,Meyer J,Tillotson G.Evaluation of the clinical microbiology profile of moxifloxacin[J].Clon Infect Dis,2001,32 (Suppl 1):51-63.
  • 5Stass H,Dalhoff A,Kubitza D,et al.Pharmacokinetics,Safety,and Tolerability of Ascending Single Doses of Moxifloxacin,a New 8-Methoxy Quinolone,Administered to Healthy Subjects[J].Antimicrobial Agents and Chemotherapy,1998,42(8):2060-2065.
  • 6Stass H,Kubitza D,Schuhly,et al.Pharmacokinetics,Safety and Tolerability of Moxifloxacin,a Novel 8-Methoxyfluoroquinolone,after Repeated Oral Administration[J].Clinical Pharmacokinetics,2001,40 (S1):1-9.
  • 7Sullivan JT,Woodruff M,Lettieri J,et al.Pharmacokinetics of a Once-Daily Oral Dose of Moxifloxacin (Bay 12-8039),a New Enantiomerically Pure 8-Methoxy Quinolone[J].Antimicrob Agents Chemother,1999,43 (11):2793-2797.
  • 8Sullivan JT,Lettieri JT,Liu P,et al.The influence of age and gender on the pharmacokinetics of moxifloxacin[J].Clinical Pharmacokinetics,2001,40 (sup-pl 1):11-18.
  • 9Lettieri J,Vargas R,Agarwal V,et al.Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers[J].Clin Pharmacokinet,2001,40 (Suppl 1):19-25.
  • 10Stass H,Kubitza D.Effects of dairy products on the oral bioavailability of moxifloxacin,a novel 8-methoxyfluoroquinolone,in healthy volunteers[J].Clin Pharmacokinet,2001,40 (Suppl 1):33-38.

共引文献11

同被引文献40

引证文献7

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部